JP2020522571A5 - - Google Patents

Download PDF

Info

Publication number
JP2020522571A5
JP2020522571A5 JP2020516959A JP2020516959A JP2020522571A5 JP 2020522571 A5 JP2020522571 A5 JP 2020522571A5 JP 2020516959 A JP2020516959 A JP 2020516959A JP 2020516959 A JP2020516959 A JP 2020516959A JP 2020522571 A5 JP2020522571 A5 JP 2020522571A5
Authority
JP
Japan
Prior art keywords
item
patient
day
pharmaceutical composition
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020516959A
Other languages
English (en)
Japanese (ja)
Other versions
JP7348171B2 (ja
JP2020522571A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/064768 external-priority patent/WO2018224498A1/en
Publication of JP2020522571A publication Critical patent/JP2020522571A/ja
Publication of JP2020522571A5 publication Critical patent/JP2020522571A5/ja
Priority to JP2023084336A priority Critical patent/JP7657855B2/ja
Application granted granted Critical
Publication of JP7348171B2 publication Critical patent/JP7348171B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020516959A 2017-06-05 2018-06-05 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画 Active JP7348171B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023084336A JP7657855B2 (ja) 2017-06-05 2023-05-23 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515268P 2017-06-05 2017-06-05
US62/515,268 2017-06-05
PCT/EP2018/064768 WO2018224498A1 (en) 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023084336A Division JP7657855B2 (ja) 2017-06-05 2023-05-23 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画

Publications (3)

Publication Number Publication Date
JP2020522571A JP2020522571A (ja) 2020-07-30
JP2020522571A5 true JP2020522571A5 (enExample) 2021-07-26
JP7348171B2 JP7348171B2 (ja) 2023-09-20

Family

ID=62620835

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020516959A Active JP7348171B2 (ja) 2017-06-05 2018-06-05 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画
JP2023084336A Active JP7657855B2 (ja) 2017-06-05 2023-05-23 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023084336A Active JP7657855B2 (ja) 2017-06-05 2023-05-23 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画

Country Status (12)

Country Link
US (2) US11980621B2 (enExample)
EP (1) EP3634418A1 (enExample)
JP (2) JP7348171B2 (enExample)
KR (2) KR20250117836A (enExample)
CN (1) CN110996956A (enExample)
AU (2) AU2018280742B2 (enExample)
CA (1) CA3066190A1 (enExample)
EA (1) EA201992612A1 (enExample)
MA (1) MA49256A (enExample)
MX (1) MX2019014483A (enExample)
SG (1) SG11201911598WA (enExample)
WO (1) WO2018224498A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2912929T5 (en) 2016-09-30 2025-05-09 Sumitomo Pharma Switzerland Gmbh Methods of treating uterine fibroids and endometriosis
US11980621B2 (en) 2017-06-05 2024-05-14 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
EP4509173A3 (en) 2017-06-05 2025-06-04 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
MA54058A (fr) 2018-10-29 2021-09-08 ObsEva SA Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale
EP4009977A2 (en) * 2019-08-08 2022-06-15 ObsEva S.A. Compositions and methods for the treatment of estrogen-dependent disorders
CN113384581B (zh) * 2020-03-12 2023-11-14 成都倍特药业股份有限公司 一种包含促性腺激素释放激素拮抗剂的药物组合物
CA3185151A1 (en) 2020-05-29 2021-12-02 Myovant Sciences Gmbh Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
EP4243829A1 (en) * 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
WO2022179469A1 (zh) * 2021-02-23 2022-09-01 南京明德新药研发有限公司 噻吩并嘧啶二酮类化合物及其应用
CN115232144B (zh) * 2021-04-22 2024-04-02 长春金赛药业有限责任公司 含氮稠环类衍生物、药物组合物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342760A (en) 1992-06-10 1994-08-30 Abbott Laboratories Determination of estradiol by competitive immunoassay
US5663054A (en) 1995-03-03 1997-09-02 Abbott Laboratories Determination of steroids by competitive immunoassay
US7109171B2 (en) 2000-02-28 2006-09-19 Praecis Pharmaceuticals Inc. Methods for treating FSH related conditions with GnRH antagonists
AU7102201A (en) 2000-07-05 2002-01-14 Yamanouchi Pharma Co Ltd Propane-1,3-dione derivatives
PT1591446E (pt) 2003-01-29 2013-06-12 Takeda Pharmaceutical Compostos de tienopirimidina e sua utilização
CA2531508C (en) 2003-07-07 2013-10-08 Neurocrine Biosciences, Inc. Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
RU2404973C2 (ru) 2005-03-31 2010-11-27 Астеллас Фарма Инк. Производное соединение пропан-1,3-диона или его соль
RU2418803C2 (ru) * 2005-10-19 2011-05-20 Киссеи Фармасьютикал Ко., Лтд. Конденсированное гетероциклическое производное, содержащая его лечебная композиция и ее применение в медицине
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
CA2788533C (en) 2010-02-10 2018-03-06 Kissei Pharmaceutical Co., Ltd. Choline salt of fused heterocyclic derivative and pharmaceutical composition containing the same
PE20141699A1 (es) 2012-01-16 2014-11-29 Bayer Ip Gmbh Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
US20130224771A1 (en) 2012-02-21 2013-08-29 Northwestern University Anti-mullerian hormone detection in whole blood
JP6222094B2 (ja) 2012-09-07 2017-11-01 アステラス製薬株式会社 スルホニルアミジン化合物の製造法
WO2014042176A1 (ja) 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
PT3415517T (pt) 2012-09-28 2022-05-13 Takeda Pharmaceuticals Co Forma cristalina de 1-(4-1-(2,6-difluorobenzil)-5- dimetilaminometil-3-(6-metoxipiridazin-3-il)-2,4-dioxo- 1,2,3,4-tetrahidrotieno(2,3-d)-pirimidin-6-il)fenil)-3- metoxiureia
WO2014143669A1 (en) 2013-03-15 2014-09-18 AbbVie Inc . Compositions for use in treating heavy menstrual bleeding and uterine fibroids
AR095785A1 (es) 2013-04-09 2015-11-11 Bayer Pharma AG Derivados de espiroindolina y composiciones farmacéutica de los mismos
US9949974B2 (en) 2015-09-01 2018-04-24 Abbvie Inc. Methods of adminstering elagolix
BR112019002513A2 (pt) 2016-08-08 2019-05-14 Kissei Pharmaceutical Co., Ltd. uso e dosagem de agentes terapêuticos para endometriose
ES2912929T5 (en) 2016-09-30 2025-05-09 Sumitomo Pharma Switzerland Gmbh Methods of treating uterine fibroids and endometriosis
US11980621B2 (en) 2017-06-05 2024-05-14 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
EP4509173A3 (en) 2017-06-05 2025-06-04 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
US20230067378A1 (en) 2018-11-07 2023-03-02 ObsEva S.A. Compositions and methods for the treatment of estrogen-dependent disorders

Similar Documents

Publication Publication Date Title
TWI314053B (en) Use of compounds that are effective as selective opiate receptor modulators
KR20240099142A (ko) 병용 요법
JP2022506368A5 (enExample)
JP2023113715A (ja) 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画
JP2020522525A5 (enExample)
AU2009238379A1 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
US20230018765A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
CA2746787A1 (en) Method of increasing testosterone and related steroid concentrations in women
NO334991B1 (no) Blandinger for å øke testosteron og beslektede konsentrasjoner av steroid hos kvinner
EP0747054B1 (en) Methods for minimizing bone loss
US20040067918A1 (en) Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
JP2003509467A5 (enExample)
JP2005526022A5 (ja) 関節リウマチの処置
JP2024529777A (ja) ARNiとカルシウムイオンアンタゴニストとの医薬組成物および応用
CN102421450B (zh) 治疗虚弱的方法
MXPA04009039A (es) Combinacion de un antagonista de los receptores de la aldosterona y un agente secuestrante de los acidos biliares.
JP2006306872A (ja) 選択的エストロゲン受容体修飾因子及びアロマターゼ阻害剤の組み合わせよりなる医薬組成物及び方法
AU2005269052A1 (en) Combination comprising a BCRP inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
JP2019524846A (ja) 子宮内膜症の治療のための投与レジメン
AU2016370297A1 (en) Combination therapy for cancer
JP2026500731A (ja) 医薬組合せおよび医薬組成物、ならびにその使用方法
Agrawal et al. Topical Nitroglycerin: A New and Safe Treatment Option for Osteoporosis
Agarwal et al. Topical Nitroglycerin for Osteoporosis: Old Drug New Application
TW200906406A (en) Use of a compound that is a neurokinin A NK2 receptor antagonist for the preparation of medicaments for use in the prevention and treatment of sexual dysfunctions
JP2005531622A5 (enExample)